Integrity, Innovation, Tenacity and Excellence

Solving the unmet clinical needs of patients is the driving force of AlphaMa

Integrity, Innovation, Tenacity and Excellence
Solving the unmet clinical needs of patients is the driving force of AlphaMa
DEL AI-Based DEL Design DEL Construction DEL Data Decoding DEL Data Analysis Hits Hits
Multi-target Activity Profiling ADMET Profiling
AI ScaffHop Deep Generative Model AI-Based Hit Triaging TransformerCPI Hits

AI + DEL

Backend on our AI technology platform and the DEL-AI integrated platform (DELAI), we develop tailored computational models and algorithm logic to quickly find active molecules for target verification and the subsequent hit-to-lead optimization. Our goal is to use AI and DEL technology to accelerate drug research and development, and bring to society drugs with clinical demand. We sincerely look forward to working with partners to achieve this goal.
  • αTranslate
  • αScaffHop
  • αCoCrystal
  • αADMET
  • αKinomeX
  • αDEL
  • Data, algorithms and computing power are indispensable factors for the development of AI technology. In the field of medicine, data is even more precious. αTranslate is a drug information extraction software that can automatically divide the areas containing chemical structural formulas from electronic publications such as journals and patents, and complete the identification and storage of chemical structures. The software is fast and accurate, which will greatly promote Collection and extraction of drug R&D big data.
  • One of the most prominent and unsolved problems in drug discovery is the efficient exploration of the vast drug-like chemical space to discover synthesizable and novel chemical structures with desired biological properties. αScaffHop generates new compounds by applying expert-defined transformation rules to initial compounds. The resulting novel structures have outstanding advantages in terms of novelty, diversity, and three-dimensional spatial coverage.
  • Making co-crystals of drugs and edible ligands is an important means to improve drug physicochemical properties, improve bioavailability and break through existing crystal form patents. αCoCrystal developed a virtual screening model for co-crystal ligands based on the massive co-crystal data in the crystal structure library. The model can quickly traverse the ligand list provided by the user, providing reference and guidance for further experimental screening.
  • Desirable absorption, distribution, metabolism, excretion and toxicity (ADMET) properties are critical for successful drug candidate selection. Accurately predicting the properties of ADMET compounds will greatly improve the efficiency of drug development. αADMET has built a systematic ADMET property prediction tool based on the existing data through the fusion of various algorithms, which has outstanding advantages in comprehensiveness, accuracy and efficiency.
  • Protein kinases have always been the focus of drug discovery research, and they play an important role in human cancer, inflammation, and Alzheimer's disease. Selectivity and pleiotropic pharmacological effects in the human kinase profile are challenging research goals. αKinomeX utilizes existing datasets to virtually screen potential inhibitors of kinases through computational methods and analyze multiple pharmacological effects, thereby efficiently guiding experimental design and drug discovery.
  • DEL technology is currently a popular new technology for drug research and development. Alphama has a professional team and equipment, and has a complete technical chain of library construction, screening, and data analysis. It can provide customers with diversified and customized services, aiming to accelerate the process of drug research and development.
-->

News

Keep up to date with the latest news anytime, anywhere
  • 05-24
    Alphama PatMap patent analysis platform is online！
    Development backgroundHow to quickly analyze and track the R&D progress of competitors is a problem that all new drug R&D…
    More
  • 03-22
    PatMap patent analysis software has been launched
    R&D BackgroundHow to quickly analyze and track the R&D progress of competitors is a problem that all new drug R&D…
    More
  • 09-01
    Simcere Pharmaceuticals and AlphaMa Biotech signed an exclusive license agreement for the new anti-tumor drug ALM005
    August 30th, 2021- Simcere Pharmaceutical Group Co., Ltd. (2096.HK, hereinafter referred to as "Simcere") and AlphaMa Biotechnology Co., Ltd. (hereinafter…
    More

About AlphaMa

New drug research and development driven by big data and artificial intelligence (AI)

AlphaMa
Backend on our AI technology platform and the DEL-AI integrated platform (DELAI), we develop tailored computational models and algorithm logic to quickly find active molecules for target verification and the subsequent hit-to-lead optimization. Our goal is to use AI and DEL technology to accelerate drug research and development, and bring to society drugs with clinical demand. We sincerely look forward to working with partners to achieve this goal.
More

Partner

AlphaMa teamed up with excellent partners to create a new generation of artificial intelligence technology platform
HUAWEI
Huawei’s mission is to bring digital to every person, home and organization for a fully connected, intelligent world. To this end, we will: drive ubiquitous connectivity and promote equal access to networks to lay the foundation for the intelligent world; provide the ultimate computing power to deliver ubiquitous cloud and intelligence; build powerful digital platforms to help all industries and organizations become more agile, efficient, and dynamic; redefine user experience with AI, offering consumers more personalized and intelligent experiences across all scenarios, including home, travel, office, entertainment, and fitness & health.
Simcere
Simcere Pharmaceutical is rapidly transitioning to an innovation and R&D-driven pharmaceutical company. It has been recognized as one of the top 100 pharmaceutical manufacturing enterprises of China. With the approval of the Ministry of Science and Technology, it has also established a national key laboratory of translational medicine and innovative pharmaceuticals. Adhering to the open and innovative R&D strategy, Simcere has become a strategic partner with several multinational companies and biotechnology enterprises to promote the value realization of global life science achievements in China.
Viva
Viva Biotech’s mission is to become a cradle for innovative biotechnology companies from around the world. We have developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides one-stop service for novel drug discovery and production to global pharmaceutical clients. EFS business is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas.
KS-V Peptide
Hefei KS-V Peptide Biotechnology Co., Ltd. is a high-tech enterprise dedicated to promoting innovation in peptide drug research and development globally. The company has a cutting-edge drug R&D platform based on chemical synthesis and structural biology, supported by many phenomenal technologies. They provide professional, effective and comprehensive solutions for drug discovery and preclinical development to scientific research institutes, biotechnology and pharmaceutical companies worldwide to help with complex technical issues in peptide drug design.
Zai Lab
Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development.

Partner

AlphaMa teamed up with excellent partners to create a new generation of artificial intelligence technology platform
HUAWEI
Huawei’s mission is to bring digital to every person, home and organization for a fully connected, intelligent world. To this end, we will: drive ubiquitous connectivity and promote equal access to networks to lay the foundation for the intelligent world; provide the ultimate computing power to deliver ubiquitous cloud and intelligence; build powerful digital platforms to help all industries and organizations become more agile, efficient, and dynamic; redefine user experience with AI, offering consumers more personalized and intelligent experiences across all scenarios, including home, travel, office, entertainment, and fitness & health.
Simcere
Simcere Pharmaceutical is rapidly transitioning to an innovation and R&D-driven pharmaceutical company. It has been recognized as one of the top 100 pharmaceutical manufacturing enterprises of China. With the approval of the Ministry of Science and Technology, it has also established a national key laboratory of translational medicine and innovative pharmaceuticals. Adhering to the open and innovative R&D strategy, Simcere has become a strategic partner with several multinational companies and biotechnology enterprises to promote the value realization of global life science achievements in China.
Viva
Viva Biotech’s mission is to become a cradle for innovative biotechnology companies from around the world. We have developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides one-stop service for novel drug discovery and production to global pharmaceutical clients. EFS business is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas.
KS-V Peptide
Hefei KS-V Peptide Biotechnology Co., Ltd. is a high-tech enterprise dedicated to promoting innovation in peptide drug research and development globally. The company has a cutting-edge drug R&D platform based on chemical synthesis and structural biology, supported by many phenomenal technologies. They provide professional, effective and comprehensive solutions for drug discovery and preclinical development to scientific research institutes, biotechnology and pharmaceutical companies worldwide to help with complex technical issues in peptide drug design.
Zai Lab
Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development.